Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel albumin-bound particles
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
WGI-0501 (Myxane) is an albumin-bound nanoparticle formulation of paclitaxel developed by WhiteOak. It is designed as a generic version of nab-paclitaxel (Abraxane). The drug functions as a microtubule stabilizer, interfering with the normal breakdown of microtubules during cell division, which leads to cell cycle arrest and apoptosis in cancer cells. The albumin-bound nanoparticle delivery system enhances the solubility of paclitaxel and facilitates its transport across the endothelial cell layer via the gp60 receptor-mediated pathway, potentially improving tumor penetration. It is currently being developed for the treatment of breast cancer, specifically triple-negative breast cancer (TNBC), and is following an ANDA (Abbreviated New Drug Application) regulatory track.
- Brand names
- Myxane
- Other names
- nab-paclitaxelalbumin-bound paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel albumin-bound particles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel albumin-bound particles.